Market Research Logo

Actinic (Solar) Keratosis - Pipeline Review, H2 2015

Actinic (Solar) Keratosis - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Actinic (Solar) Keratosis - Pipeline Review, H2 2015’, provides an overview of the Actinic (Solar) Keratosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Actinic (Solar) Keratosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Actinic (Solar) Keratosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Actinic (Solar) Keratosis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Actinic (Solar) Keratosis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Actinic (Solar) Keratosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Actinic (Solar) Keratosis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Actinic (Solar) Keratosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Actinic (Solar) Keratosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Actinic (Solar) Keratosis Overview
Therapeutics Development
Pipeline Products for Actinic (Solar) Keratosis - Overview
Pipeline Products for Actinic (Solar) Keratosis - Comparative Analysis
Actinic (Solar) Keratosis - Therapeutics under Development by Companies
Actinic (Solar) Keratosis - Therapeutics under Investigation by Universities/Institutes
Actinic (Solar) Keratosis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Actinic (Solar) Keratosis - Products under Development by Companies
Actinic (Solar) Keratosis - Products under Investigation by Universities/Institutes
Actinic (Solar) Keratosis - Companies Involved in Therapeutics Development
3M Drug Delivery Systems
Advancell
Biofrontera AG
Clinuvel Pharmaceuticals Limited
Digna Biotech, S.L.
Dolorgiet Gmbh & Co. Kg
Foamix Pharmaceuticals Ltd.
G&E Herbal Biotechnology Co., Ltd.
Galderma S.A.
Kinex Pharmaceuticals, LLC
LEO Pharma A/S
Novartis AG
Novelix Pharmaceuticals, Inc.
Promius Pharma, LLC
Spherium Biomed S.L.
Actinic (Solar) Keratosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
854-A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ACT-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AD-17137 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AK-3012 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
aminolevulinic acid hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ANs-40 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ANS-401 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ANS-403 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CUV-9900 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DFD-07 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DFD-08 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
disitertide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
imiquimod - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KX-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LEO-43204 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LFX-453 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NVX-207 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Peptide for Dermatology, Immunology and Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
resiquimod - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Activate Protein Kinase C for Dermatology and Cancer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SP-12054 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SRT-100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sulindac + hydrogen peroxide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VPE-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Actinic (Solar) Keratosis - Recent Pipeline Updates
Actinic (Solar) Keratosis - Dormant Projects
Actinic (Solar) Keratosis - Discontinued Products
Actinic (Solar) Keratosis - Product Development Milestones
Featured News & Press Releases
Jun 22, 2015: Biofrontera completes final steps ahead of FDA New Drug Application in the USA
May 06, 2015: Biofrontera delivers excellent results from the Phase III study for field therapy of actinic keratosis for publication
Mar 25, 2015: Biofrontera starts Sales and Marketing of Ameluz in Spain
Jan 26, 2015: Biofrontera prepares market launch in Belgium for its non-melanoma skin cancer drug Ameluz
Jan 20, 2015: Kinex Pharmaceuticals Announces First Patient Dosed with KX2-391 Ointment for Actinic Keratosis in a Phase 1 Clinical Study
Nov 26, 2014: Further Progress In International Approval Processes Of Biofrontera's Ameluz
Oct 08, 2014: US Regulatory Authority Gives Green Light To Proposed Approach Towards Approval Of Ameluz In The USA
Oct 02, 2014: Clinical Program For US Approval Of Ameluz Approaches Completion: Studies Confirm Excellent Efficacy And Safety
Aug 21, 2014: Biofrontera AG: Pre-NDA meeting scheduled with FDA for the approval of Ameluz and B-RhodoLED
Aug 20, 2014: Biofrontera files litigation against former supplier
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Actinic (Solar) Keratosis, H2 2015
Number of Products under Development for Actinic (Solar) Keratosis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015
Actinic (Solar) Keratosis - Pipeline by 3M Drug Delivery Systems, H2 2015
Actinic (Solar) Keratosis - Pipeline by Advancell, H2 2015
Actinic (Solar) Keratosis - Pipeline by Biofrontera AG, H2 2015
Actinic (Solar) Keratosis - Pipeline by Clinuvel Pharmaceuticals Limited, H2 2015
Actinic (Solar) Keratosis - Pipeline by Digna Biotech, S.L., H2 2015
Actinic (Solar) Keratosis - Pipeline by Dolorgiet Gmbh & Co. Kg, H2 2015
Actinic (Solar) Keratosis - Pipeline by Foamix Pharmaceuticals Ltd., H2 2015
Actinic (Solar) Keratosis - Pipeline by G&E Herbal Biotechnology Co., Ltd., H2 2015
Actinic (Solar) Keratosis - Pipeline by Galderma S.A., H2 2015
Actinic (Solar) Keratosis - Pipeline by Kinex Pharmaceuticals, LLC, H2 2015
Actinic (Solar) Keratosis - Pipeline by LEO Pharma A/S, H2 2015
Actinic (Solar) Keratosis - Pipeline by Novartis AG, H2 2015
Actinic (Solar) Keratosis - Pipeline by Novelix Pharmaceuticals, Inc., H2 2015
Actinic (Solar) Keratosis - Pipeline by Promius Pharma, LLC, H2 2015
Actinic (Solar) Keratosis - Pipeline by Spherium Biomed S.L., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Actinic (Solar) Keratosis Therapeutics - Recent Pipeline Updates, H2 2015
Actinic (Solar) Keratosis - Dormant Projects, H2 2015
Actinic (Solar) Keratosis - Dormant Projects (Contd..1), H2 2015
Actinic (Solar) Keratosis - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Actinic (Solar) Keratosis, H2 2015
Number of Products under Development for Actinic (Solar) Keratosis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report